氢化麦角碱治疗急性缺血性脑血管病的临床研究

The Test of Clinical Efficacy and Safety of Dihydroergoxine in the Treatment of Acute Ischemic Cerebrovascular Disease

目的 评价氢化麦角碱(dihydroergotoxine, DHET)治疗急性缺血性脑血管病的临床疗效及安全性。方法 入选病例随机分为3组:A、B组每日分别静脉点滴0 6、1 5 mg DHET,C组每日静脉点滴复方丹参 40 mL作为对照,每组30例。3组均于治疗前和治疗后第4、10、14天采用斯堪得维亚脑卒中量表(Scandinavian strokescale, SSS)评分标准对患者进行评分。结果 3组治疗前后 SSS评分差异均具显著性 (均 P<0 .05)。结论 DHET 对急性缺血性脑血管病有较好疗效且副反应少。

Objective To test the clinical efficacy and safety of dihydroergoxine in the treatment of acute ischemic cerebrovascular disease. Methods All selected cases were randomly divided into three groups, each contains 30 cases. In the frist group, dihydroergoxine 06 mg/d intravenous dripped; In the second group, dihydroergoxine 15 mg/d intravenous dripped; And in the third group, compound salvia miltorrhize 40 mL/d intravenous dripped as control. All patients in the three groups were scored according to scandinavian stroke scale (SSS) before and 4 , 10 ,14 days after the treatment. Results The SSS scores before and after treatment differed significantly in all three groups (P=0000, P =0000, P <0005) Conclusions Dihydroergoxine has marked efficacy and less side-effects in the treatment of acute ischemic cerebrovascular disease.